Member Login
Logout
Voyager Toolkit
Become a Voyager

Jeff Martin, PhD

Cancer biologist. Early-stage biotech consultant. Founder at FLYTE Bio

SAB Made Human Antibodies in Cows. Four T1D Patients Kept Their Insulin.

SAB Biotherapeutics reported Phase 1 data for SAB-142 in four established Type 1 diabetes patients.

ModeX Dosed a Tetraspecific. The T Cell Engager Field Just Got More Crowded.

ModeX Therapeutics dosed the first patient with MDX2003, a tetraspecific T-cell engaging antibody in B-cell lymphoma.

Nurix Brought Three Degraders to AACR. Two of Them Cross Into the Brain.

Nurix Therapeutics presented preclinical data on three protein degradation assets at AACR 2026.

BlossomHill’s Pan-KRAS Inhibitor Sticks to the Target for 54 Hours

BlossomHill Therapeutics unveiled pan-KRAS inhibitor BH-501284 at AACR 2026 with sub-nanomolar potency.

NETRIS Got Pancreatic Cancer Data Into Nature. The Number That Matters Is 40%.

NETRIS Pharma published Phase 1b data for anti-netrin-1 antibody NP137 in pancreatic cancer in Nature.

10x Science Got $4.8M to Read Mass Spec Data Like a Biologist

10x Science raised $4.8M seed led by Initialized to automate protein characterization with AI.

Dewpoint Cut 70% of Staff. Now They’re Chasing MYC.

Dewpoint Therapeutics presents preclinical data on an oral MYC condensate modulator at AACR 2026.

Rznomics Rewrites Liver Cancer RNA. 23% Complete Response.

Rznomics shows 61.5% response rate and 23% complete responses in HCC with its RNA ribozyme platform.

GEn1E Paid Its Manufacturer in Equity. That’s the Real Story.

GEn1E Lifesciences brings on Rubicon Research as a manufacturing partner with equity and milestone-based compensation.

Medicenna Thinks They Can Figure Out IL-2. Are They Right?

Medicenna presents preclinical NHP data for MDNA113, a conditionally activated PD-1 × IL-2 bifunctional, with IND planned H2 2026.

Ray Therapeutics Pulls $125M From An All-Star Roster Of Investors

Ray Therapeutics closes an upsized $125M Series B to advance its optogenetic gene therapy for retinitis pigmentosa.

Jeff Jonas Raised $106M. Then Bought Programs From Eisai and Hansoh.

Tortugas Neuroscience launches with $106M and two in-licensed clinical-stage assets from Eisai and Hansoh.

Dewpoint Cut 70% of Staff. Now They’re Chasing MYC.

Dewpoint Therapeutics presents preclinical data on an oral MYC condensate modulator at AACR 2026.

Rznomics Rewrites Liver Cancer RNA. 23% Complete Response.

Rznomics shows 61.5% response rate and 23% complete responses in HCC with its RNA ribozyme platform.

Ray Therapeutics Pulls $125M From An All-Star Roster Of Investors

Ray Therapeutics closes an upsized $125M Series B to advance its optogenetic gene therapy for retinitis pigmentosa.

Jeff Jonas Raised $106M. Then Bought Programs From Eisai and Hansoh.

Tortugas Neuroscience launches with $106M and two in-licensed clinical-stage assets from Eisai and Hansoh.

Immunofoco Already Has a Phase 3 CAR-T. Now It’s Making Them Inside the Patient.

Immunofoco presented preclinical data for IMV102, an in vivo BCMA CAR-T built on its iMAGIC lentiviral platform.

EpiBiologics Is Taking Extracellular Protein Degradation Into The Clinic

EpiBiologics dosed the first patient with EPI-326, a bispecific antibody degrader hitting wild-type and mutant EGFR.

A 488-Amino-Acid CRISPR That Fits Inside an AAV

Metagenomi published a compact Cas12f CRISPR variant small enough for single-AAV delivery, with editing activity that rivals larger systems.

A Chinese Biotech Just Filed the World’s First LILRB4 T Cell Engager

Mabwell's 6MW5311 became the first LILRB4/CD3 bispecific T cell engager to reach clinical submission anywhere in the world.

67% in Ovarian. 50% in Prostate. Without the Bone Marrow Beating.

Acerand Therapeutics drops Phase I/II data for ACE-106, a PARP1-selective inhibitor with response rates that put it in best-in-class territory.

20 Minutes to Burn a Pancreatic Tumor

Sonire Therapeutics closes $18M Series A for focused ultrasound ablation in pancreatic cancer.

Lilly Bought a Dual-Payload ADC Before It Hit the Clinic. Here’s Why.

Eli Lilly acquires CrossBridge Bio and its dual-payload ADC platform before any clinical data.

FDA Breakthrough for a Urine-Based Cancer Test

TOBY Inc receives FDA Breakthrough Device Designation for a urine-based multi-cancer early detection test.

ViewsML Raises $4.8M Seed With Plans To Replace Tissue Staining With AI.

ViewsML closed a $4.9M seed for AI virtual biomarker staining from standard pathology images.

Novo Nordisk Called OpenAI. So Did Everyone Else.

Novo Nordisk partners with OpenAI as AI drug discovery deal flow surpasses $5B in five months.

One Bought a Podcast. The Other Bought a Lab.

Anthropic dropped $400M on a 9-person biotech AI startup. The same day, OpenAI bought a podcast. That tells you everything.

$787 Million Says AI Can Design Better Biologics Than You

An AI-native biologics company just raised $787M with Sanofi and a Pfizer/Hillhouse fund backing it — and they already have a Phase 2 asset.

Teaching a Gene Editor to Optimize Itself

Specific Biologics just got government funding to build a machine learning layer on top of its Dualase gene editing platform — targeting repeat expansion diseases like ALS.

Molecular Glues Were Discovered by Accident. Not Anymore.

Molecular glues are biotech's hottest modality and its hardest to design rationally. Ternary thinks AI can change that.

220 Targets. Zero Antibodies. One AI Platform.

One-third of all FDA-approved drugs target GPCRs, but almost no antibodies do. Antiverse's AI platform is changing that — and the CF Foundation just signed on.

Immunofoco Already Has a Phase 3 CAR-T. Now It’s Making Them Inside the Patient.

Immunofoco presented preclinical data for IMV102, an in vivo BCMA CAR-T built on its iMAGIC lentiviral platform.

EpiBiologics Is Taking Extracellular Protein Degradation Into The Clinic

EpiBiologics dosed the first patient with EPI-326, a bispecific antibody degrader hitting wild-type and mutant EGFR.

Lilly Bought a Dual-Payload ADC Before It Hit the Clinic. Here’s Why.

Eli Lilly acquires CrossBridge Bio and its dual-payload ADC platform before any clinical data.

An Auger-Emitting Radioconjugate for Triple-Negative Breast Cancer

Cellectar Biosciences enrolls first patient in Phase 1b of CLR 125, an iodine-125 Auger emitter targeting refractory TNBC.

Deck Bio’s T Cell Engagers Target Multiple Intracellular Targets. That’s a Big Deal.

Deck Bio launches a multi-target pMHC T cell engager platform that hits multiple intracellular cancer antigens with a single binder.

“Cue” The Music. $7.5M for Picking the Right Molecule.

Cue Biopharma earns a $7.5M preclinical milestone from Boehringer Ingelheim for its CUE-501 autoimmune program.

An Oral Pill for Glioblastoma. From Oslo.

Hemispherian doses first patients in a Phase 1/2a trial of GLIX1, a first-in-class oral TET2 activator for glioblastoma.

One Patient. One B Cell. A Whole New Playbook.

Immusoft presents the world's first engineered B cell therapy patient data at an FDA workshop.

Edit the RNA. Keep the DNA. Fix the Disease.

AIRNA doses first patient in Phase 1 of AIR-001, an RNA-editing therapy for alpha-1 antitrypsin deficiency.

ADCs Hit a Wall. This Company Brought a Different Weapon.

ABION shows preclinical data at AACR 2026 where its IFN-β antibody fusion ABN202 outperformed TROP2 ADCs in resistant tumors.

Your Knee Called. It Wants New Cartilage.

Renovare Therapeutics launches from stealth with up to $33.5M in ARPA-H funding for osteoarthritis regeneration.

No Drugs. Just Ultrasound.

SonoNeu exits stealth with $5.2M from a $41.3M ARPA-H program to bring sonogenetics to the clinic.
Home
Login
Logout
Become a Voyager
All
Emerging Modalities
AI In Biotech
Landscape Reports
Advanced Search
Live Show
Featured Companies
Search
Useful links
About Us
Privacy Policy
Terms of Use

Voyager Toolkit

Advanced Signal Search
Landscape Reports
More coming soon...